Platinum-based chemotherapy remains the cornerstone for the first-line treatment of platinum-eligible patients with advanced urothelial cancer. Chemotherapy combinations with other agents did not improve survival in the front-line setting. It is unclear if targeting DNA damage repair pathways augments the efficacy of cisplatin-based chemotherapy.